This finding highlights the functional relevance of IMiD's inherent polypharmacology in circumventing primary resistance mechanisms at the cellular level. Together, our results identify the ARID2-containing PBAF complex as a critical vulnerability in resistant myeloma cells and provide a mechanistic rationale for designing combination strategies that co-target this complex, with the potential to enhance therapeutic efficacy by overcoming drug resistance.

In vivo experimental results demonstrated that oral administration of this IFX formulation in colitis-induced mice significantly reduced the levels of pro-inflammatory cytokines (TNF-α and IL-6) and myeloperoxidase (MPO), and effectively alleviated colonic tissue damage. This IFX formulation exhibits excellent potential for oral antibody delivery, with enhanced targeting efficiency and reduced systemic toxicity, thus promising to provide a novel clinically translatable strategy for IBD treatment.

P1/2, N=30, Not yet recruiting, Erasmus Medical Center

P=N/A, N=300, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

P2, N=150, Recruiting, Navigator Medicines, Inc.

The complementary activity of lirafugratinib and futibatinib against FGFR2 kinase domain mutations supports their sequential use, when precise resistance mutations are detected in patients.

P1/2, N=14, Active, not recruiting, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Trial completion date: Jun 2026 --> Feb 2027 | Trial primary completion date: Dec 2025 --> Jan 2027

P2, N=2, Terminated, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Apr 2029 --> Jul 2025 | Withdrawn --> Terminated | Trial primary completion date: Sep 2028 --> Jul 2025; The study is being closed early due to insufficient participant enrollment across study sites.

IFX + AZA for rapid induction remission and RIF+AZA for maintenance therapy in IBD.

P=N/A, N=300, Recruiting, Nanfang Hospital, Southern Medical University; Nanfang Hospital, Southern Medical University

P=N/A, N=30, Recruiting, Children's Hospital,Zhejiang University School of Medicine; Children's Hospital,Zhejiang University School of Medicine

Patients with high and low RF levels experienced similar clinical responses to CZP treatment, irrespective of previous inadequate responses or intolerance to TNFis. These findings expand previous observations, supporting CZP as an effective treatment for patients with RA who have high RF levels and prior inadequate responses to TNFis.